One hundred years of respiratory medicine chronic obstructive pulmonary disease (COPD)-Republished article

Respiratory Medicine: COPD Update

Volumn 4, Issue 1, 2008, Pages 8-25

  Cazzola, Mario ^a   Donner, Claudio ^b   Hanania, Nicola A ^c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b Mondo Medico   (Italy)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Chronic bronchitis; COPD; Emphysema

Indexed keywords

ACETYLCYSTEINE; ALMITRINE DIMESILATE; AZITHROMYCIN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CETIRIZINE; CILOMILAST; CORTICOSTEROID; FLUTICASONE PROPIONATE; FORMOTEROL; GEMIFLOXACIN; ISOPRENALINE; MEDROXYPROGESTERONE ACETATE; METHYLPREDNISOLONE; MONTELUKAST; MOXIFLOXACIN; MUCOLYTIC AGENT; NOVOBIOCIN; OXYTETRACYCLINE; PLACEBO; PREDNISOLONE; REBAMIPIDE; ROFLUMILAST; SALBUTAMOL; SALMETEROL; TELITHROMYCIN; TESTOSTERONE; THEOPHYLLINE; TIOTROPIUM BROMIDE; UNINDEXED DRUG;

AIR POLLUTION; AIRWAY OBSTRUCTION; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BRONCHUS MUCUS; CHILDHOOD DISEASE; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; DISEASE SEVERITY; DRUG INDICATION; DRUG USE; DUST; DYSPNEA; EMPHYSEMA; ENZYME DEFICIENCY; HISTORY OF MEDICINE; HUMAN; INFECTION; INFLAMMATION; LOW DRUG DOSE; MUCUS SECRETION; OCCUPATIONAL EXPOSURE; OXYGEN THERAPY; PATHOGENESIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; PULMONARY REHABILITATION; RISK FACTOR; SURVIVAL RATE;

EID: 37849040834     PISSN: 17450454     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmedu.2007.11.019     Document Type: Article

References (249)

1. Rimington J. Chronic bronchitis, smoking and social class: a study among working people in the towns of Mid and East Cheshire. Br J Dis Chest 63 (1969) 193-205
2. Rimington J. Cigarette smokers' chronic bronchitis: inhalers and non-inhalers compared. Br J Dis Chest 68 (1974) 161-165
3. Siafakas N.M., and Tzortzaki E.G. Few smokers develop COPD. Why?. Respir Med 96 (2002) 615-624
4. 1antitrypsin deficiency: the clinical and physiological features of pulmonary emphysema in subjects homozygous for Pi type Z: a survey by the British Thoracic Association. Br J Dis Chest 77 (1983) 14-27
5. Semple P., Reid C.B., and Thompson W.D. Widespread panacinar emphysema with alpha-1-antitrypsin deficiency. Br J Dis Chest 74 (1980) 289-295
6. Stuart-Harris C.H. The epidemiology and evolution of chronic bronchitis. Br J Tuberc Dis Chest 48 (1954) 169-178
7. Caplin M., Capel L.H., and Wheeler W.F. A bronchitis registry in East London. Br J Dis Chest 58 (1964) 97
8. Caplin M., and Silver C.P. The unemployment problems associated with chronic bronchitis in East London. Br J Dis Chest 54 (1960) 297-307
9. Halpern M.T., Stanford R.H., and Borker R. The burden of COPD in the USA: results from the confronting COPD survey. Respir Med 97 Suppl 3 (2003) S81-S89
10. Mannino D.M., and Holguin F. Epidemiology and global impact of chronic obstructive pulmonary disease. Respir Med: COPD Update 1 (2006) 114-120
11. Mannino D.M., Doherty D.E., and Buist A.S. Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) Study. Respir Med 100 (2006) 115-122
12. Vermeire P. The burden of chronic obstructive pulmonary disease. Respir Med 96 (2002) S3-S10
13. O'Brien J.A., Ward A.J., Jones M.K.C., McMillan C., and Lordan N. Utilization of health care services by patients with chronic obstructive pulmonary disease. Respir Med 97 Suppl 1 (2003) S53-S58
14. Wilson L., Devine E.B., and So K. Direct medical costs of chronic obstructive pulmonary disease: chronic bronchitis and emphysema. Respir Med 94 (2000) 204-213
15. Ward M.M., Javitz H.S., Smith W.M., and Bakst A. Direct medical cost of chronic obstructive pulmonary disease in the USA. Respir Med 94 (2000) 1123-1129
16. Jacobson L., Hertzman P., Löfdahl C.G., Skoogh B.E., and Lindgren B. The economic impact of asthma and chronic obstructive pulmonary disease (COPD) in Sweden in 1980 and 1991. Respir Med 94 (2000) 247-255
17. Rutten-van Mölken M.P.M.H., Postma M.J., Joore M.A., Van Genugten M.L.L., Leidl R., and Jager J.C. Current and future medical costs of asthma and chronic obstructive pulmonary disease in the Netherlands. Respir Med 93 (1999) 779-787
18. Wouters E.F.M. Economic analysis of the confronting COPD survey: an overview of results. Respir Med 97 Suppl 3 (2003) S3-S14
19. Mapel D.W., McMillan G.P., Frost F.J., Hurley J.S., Picchi M.A., Lydick E., et al. Predicting the costs of managing patients with chronic obstructive pulmonary disease. Respir Med 99 (2005) 1325-1333
20. Andersson F., Borg S., Jansson S.-A., Jonsson A.-C., Ericsson A., Prütz C., et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med 96 (2002) 700-708
21. Mannino D.M., Homa D.M., Akinbami L.J., Ford E.S., and Redd S.C. Chronic obstructive pulmonary disease surveillance-United States 1971-2000. MMWR Surveill Summ 51 6 (2002) 1-16
22. Dransfield M.T., Davis J.J., Gerald L.B., and Bailey W.C. Racial and gender differences in susceptibility to tobacco smoke among patients with chronic obstructive pulmonary disease. Respir Med 100 (2006) 1110-1116
23. Watson L., Vestbo J., Postma D.S., Decramer M., Rennard S., Kiri V.A., et al. Gender differences in the management and experience of chronic obstructive pulmonary disease. Respir Med 98 (2004) 1207-1213
24. Hardie J.A., Vollmer W.M., Buist A.S., Bakke P., and Mørkve O. Respiratory symptoms and obstructive pulmonary disease in a population aged over 70 years. Respir Med 99 (2005) 186-195
25. Lundbäck B., Lindberg A., Lindström M., Rönmark E., Jonsson A.C., Jönsson E., et al. Not 15 but 50% of smokers develop COPD?-Report from the obstructive lung disease in Northern Sweden Studies. Respir Med 97 (2003) 115-122
26. Peruzza S., Sergi G., Vianello A., Pisent C., Tiozzo F., Manzan A., et al. Chronic obstructive pulmonary disease (COPD) in elderly subjects: impact on functional status and quality of life. Respir Med 97 (2003) 612-617
27. Yohannes A.M., Roomi J., Waters K., and Connolly M.J. Quality of life in elderly patients with COPD: measurement and predictive factors. Respir Med 92 (1998) 1231-1236
28. Simpson T. The emphysema problem. Br J Dis Chest 62 (1968) 188-194
29. Reid L. Emphysema: classification and clinical significance. Br J Dis Chest 60 (1966) 57-65
30. Wardman A.G., Binns V., Clayden A.D., and Cooke N.J. The diagnosis and treatment of adults with obstructive airways disease in general practice. Br J Dis Chest 80 (1986) 19-26
31. Kai K.M., Beeh M., Kornmann O., Beier J., Ksoll M., and Buhl R. Clinical application of a simple questionnaire for the differentiation of asthma and chronic obstructive pulmonary disease. Respir Med 98 (2004) 591-597
32. Müllerová H., Wedzicha J., Soriano J.B., and Vestbo J. Validation of a chronic obstructive pulmonary disease screening questionnaire for population surveys. Respir Med 98 (2004) 78-83
33. Freeman D., Nordyke R.J., Isonaka S., Nonikov D.V., Maroni J.M., Price D., et al. Questions for COPD diagnostic screening in a primary care setting. Respir Med 99 (2005) 1311-1318
34. Griffiths C., Feder G., Wedzicha J., Foster G., Livingstone, and Singh Marlowe G. Feasibility of spirometry and reversibility testing for the identification of patients with chronic obstructive pulmonary disease on asthma registers in general practice. Respir Med 93 (1999) 903-908
35. 6 predicts lung function decline in adult smokers. Respir Med 96 (2002) 444-449
36. Quadrelli S.A., Roncoroni A.J., and Montiel G.C. Evaluation of bronchodilator response in patients with airway obstruction. Respir Med 93 (1999) 630-636
37. Collins J.V. Closing volume-a test of small airway function?. Br J Dis Chest 67 (1973) 1-18
38. Pride N.B. The assessment of airflow obstruction: role of measurements of airways resistance and of tests of forced expiration. Br J Dis Chest 65 (1971) 135-169
39. Iriberri M., Gáldiz J.B., Gorostiza A., Ansola P., and Jaca C. Comparison of the distances covered during 3 and 6 min walking test. Respir Med 96 (2002) 812-816
40. Stark R.D., Gambles S.A., and Chatterjee S.S. An exercise test to assess clinical dyspnoea: estimation of reproducibility and sensitivity. Br J Dis Chest 76 (1982) 269-278
41. 2 in COPD patients. Respir Med 95 (2001) 618-626
42. Miravitlles M., Ferrer M., Pont A., Viejo J., Masa J.F., Gabriel R., et al. Characteristics of a population of COPD patients identified from a population-based study. Focus on previous diagnosis and never smokers. Respir Med 99 (2005) 985-995
43. Bolton C.E., Ionescu A.A., Edwards P.H., Faulkner T.A., Edwards S.M., and Shale D.J. Attaining a correct diagnosis of COPD in general practice. Respir Med 99 (2005) 493-500
44. Miravitlles M., de la Roza C., Morera J., Montemayor T., Gobartt E., Martín A., et al. Chronic respiratory symptoms, spirometry and knowledge of COPD among general population. Respir Med 100 (2006) 1973-1980
45. Smart J., Naimi S., and Capel L.H. The relationship between effort intolerance, spirometry and blood gas analysis in patients with chronic obstructive airway disease. Br J Dis Chest 55 (1961) 6-16
46. Foglio K., Carone M., Pagani M., Bianchi L., Jones P.W., and Ambrosino N. Physiological and symptom determinants of exercise performance in patients with chronic airway obstruction. Respir Med 94 (2000) 256-263
47. Celli B.R., Calverley P.M.A., Rennard S.I., Wouters E.F.M., Agusti A., Anthonisen N., et al. Proposal for a multidimensional staging system for chronic obstructive pulmonary disease. Respir Med 99 (2005) 1546-1554
48. Sandek K., Bratel T., Lagerstrand L.H., and Rosell H. Relationship between lung function, ventilation-perfusion inequality and extent of emphysema as assessed by high-resolution computed tomography. Respir Med 96 (2002) 934-943
49. Kitaguchi Y., Fujimoto K., Kubo K., and Honda T. Characteristics of COPD phenotypes classified according to the findings of HRCT. Respir Med (2006) 1742-1752
50. Celli B.R., and MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 23 (2004) 932-946
51. Global initiative for chronic obstructive pulmonary disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease NHLBI/WHO workshop report issued April 2001. NIH publication no. 270.
52. Laitinen L.A., and Koskela K. Chronic bronchitis and chronic obstructive pulmonary disease: Finnish National Guidelines for Prevention and Treatment 1998-2007. Respir Med 93 (1999) 297-332
53. Buist A.S. Guidelines for the management of chronic obstructive pulmonary disease. Respir Med 96 Suppl 3 (2002) S11-S16
54. Tsoumakidou M., Tzanakis N., Voulgaraki O., Mitrouska I., Chrysofakis G., Samiou M., et al. Is there any correlation between the ATS, BTS, ERS and GOLD COPD's severity scales and the frequency of hospital admissions?. Respir Med 98 (2004) 178-183
55. Smith B.J., Hender K., Frith P., Crockett A.J., Cheok F., and Spedding S. Systematic assessment of clinical practice guidelines for the management of chronic obstructive pulmonary disease. Respir Med 97 (2003) 37-45
56. Gulsvik A., Gallefoss F., Dirksen A., Kinnula V., Gislason T., and Janson C. A critical evaluation of the guidelines of obstructive lung disease and their implementation. Respir Med 100 Suppl 1 (2006) S22-S30
57. Rutschmann O.T., Janssens J.-P., Vermeulen B., and Sarasin F.P. Knowledge of guidelines for the management of COPD: a survey of primary care physicians. Respir Med 98 (2004) 932-937
58. Watson L., Vonk J.M., Löfdahl C.G., Pride N.B., Pauwels R.A., Laitinen L.A., et al. Predictors of lung function and its decline in mild to moderate COPD in association with gender: results from the Euroscop study. Respir Med 100 (2006) 746-753
59. Sinclair J.D. The progress of pulmonary deficiency in emphysema. Br J Tuberc Dis Chest 49 (1955) 157-165
60. Simpson T. Chronic bronchitis and emphysema with special reference to prognosis. Br J Dis Chest 62 (1968) 57-69
61. Van Der Molen T., Pieters W., Bellamy D., and Taylor R. Measuring the success of treatment for chronic obstructive pulmonary disease-patient, physician and healthcare payer perspectives. Respir Med 96 Suppl 3 (2002) S17-S21
62. Jones P., Lareau S., and Mahler D.A. Measuring the effects of COPD on the patient. Respir Med 99 Suppl 2 (2005) S11-S18
63. Oga T., Nishimura K., Tsukino M., Sato S., Hajiro T., and Mishima M. Longitudinal deteriorations in patient reported outcomes in patients with COPD. Respir Med 101 (2007) 146-153
64. Celli B., Halpin D., Hepburn R., Byrne N., Keating E.T., and Goldman M. Symptoms are an important outcome in chronic obstructive pulmonary disease clinical trials: results of a 3-month comparative study using the Breathlessness, Cough and Sputum Scale (BCSS). Respir Med 97 Suppl 1 (2003) S35-S43
65. ©. Respir Med 97 Suppl 1 (2003) S59-S70
66. Vidotto G., Bertolotti G., Carone M., Arpinelli F., Bellia V., Jones P.W., et al. A new questionnaire specifically designed for patients affected by chronic obstructive pulmonary disease: the Italian Health Status Questionnaire. Respir Med 100 (2006) 862-870
67. Puhan M.A., Guyatt G.H., Goldstein R., Mador J., McKim D., Stahl E., et al. Relative responsiveness of the Chronic Respiratory Questionnaire, St. Georges Respiratory Questionnaire and four other health-related quality of life instruments for patients with chronic lung disease. Respir Med 101 (2007) 308-316
68. Gigliotti F., Grazzini M., Stendardi L., Romagnoli I., and Scano G. Quality of life and functional parameters in patients with chronic obstructive pulmonary disease (COPD): an update. Respir Med 96 (2002) 373-374
69. 2 in chronic obstructive pulmonary disease. Respir Med 94 (2000) 772-777
70. Hajiro T., Nishimura K., Tsukino M., Ikeda A., and Oga T. Stages of disease severity and factors that affect the health status of patients with chronic obstructive pulmonary disease. Respir Med 94 (2000) 841-846
71. Monso E., Fiz J.M., Izquierdo J., Alonso J., Coll R., Rosell A., et al. Quality of life in severe chronic obstructive pulmonary disease: correlation with lung and muscle function. Respir Med 92 (1998) 221-227
72. van Manen J.G., Bindels P.J., Dekker E.W., Ijzermans C.J., Bottema B.J., van der Zee J.S., et al. Added value of co-morbidity in predicting health-related quality of life in COPD patients. Respir Med 95 (2001) 496-504
73. González E., Herrejón A., Inchaurraga I., and Blanquer R. Determinants of health-related quality of life in patients with pulmonary emphysema. Respir Med 99 (2005) 638-644
74. Garrod R., Bestall J.C., Paul E.A., Wedzicha J.A., and Jones P.W. Development and validation of a standardized measure of activity of daily living in patients with severe COPD: the London Chest Activity of Daily Living scale (LCADL). Respir Med 94 (2000) 589-596
75. Garrod R., Paul E.A., and Wedzicha J.A. An evaluation of the reliability and sensitivity of the London Chest Activity of Daily Living Scale (LCADL). Respir Med 96 (2002) 725-730
76. Agusti A.G.N. COPD, a multicomponent disease: implications for management. Respir Med 99 (2005) 670-682
77. Decramer M., De Benedetto F., Del Ponte A., and Marinari S. Systemic effects of COPD. Respir Med 99 Suppl 2 (2005) S3-S10
78. Kinnunen T., Säynäjäkangas O., Tuuponen Y., and Keistinen T. Impact of comorbidities on the duration of COPD patients' hospital episodes. Respir Med 97 (2003) 143-146
79. Jørgensen N.R., Schwarz P., Holme I., Henriksen B.M., Petersen L.J., and Backer V. The prevalence of osteoporosis in patients with chronic obstructive pulmonary disease-a cross sectional study. Respir Med 101 (2007) 177-185
80. Antonelli Incalzi R., Incalzi R.A., Caradonna P., Ranieri P., Basso S., Fuso L., et al. Correlates of osteoporosis in chronic obstructive pulmonary disease. Respir Med 94 (2000) 1079-1084
81. Breukink S.O., Strijbos J.H., Koorn M., Koeter G.H., Breslin E.H., and van der Schans C.P. Relationship between subjective fatigue and physiological variables in patients with chronic obstructive pulmonary disease. Respir Med 92 (1998) 676-682
82. Di Marco F., Verga M., Reggente M., Maria Casanova F., Santus P., Blasi F., et al. Anxiety and depression in COPD patients: the roles of gender and disease severity. Respir Med 100 (2006) 1767-1774
83. Gudmundsson G., Gislason T., Janson C., Lindberg E., Suppli Ulrik C., Brondum E., et al. Depression, anxiety and health status after hospitalisation for COPD: a multicentre study in the Nordic countries. Respir Med 100 (2006) 87-93
84. Antonelli Incalzi R., Chiappini F., Fuso L., Torrice M.P., Gemma A., and Pistelli R. Predicting cognitive decline in patients with hypoxaemic COPD. Respir Med 92 (1988) 527-533
85. Slinde F., Grönberg A.-M., Engström C.-P., Rossander-Hulthén L., and Larsson S. Body composition by bioelectrical impedance predicts mortality in chronic obstructive pulmonary disease patients. Respir Med 99 (2005) 1004-1009
86. Vermeeren M.A.P., Creutzberg E.C., Schols A.M.W.J., Postma D.S., Pieters W.R., Roldaan A.C., et al. Prevalence of nutritional depletion in a large out-patient population of patients with COPD. Respir Med 100 (2006) 1349-1355
87. Ibáñez M., Aguilar J.J., Maderal M.A., Prats E., Fårrero E., Font A., et al. Sexuality in chronic respiratory failure: coincidences and divergences between patient and primary caregiver. Respir Med 95 (2001) 975-979
88. Millard J., and Reid L. Right ventricular hypertrophy and its relationship to chronic bronchitis and emphysema. Br J Dis Chest 68 (1974) 103-110
89. Mounsey J.P.D. Emphysema heart disease. Br J Tuberc Dis Chest 48 (1954) 63-68
90. Semmens M., and Reid L. Pulmonary arterial muscularity and right ventricular hypertrophy in chronic bronchitis and emphysema. Br J Dis Chest 68 (1974) 253-263
91. Williams I.P., Boyd M.J., Humberstone A.M., Wilson A.G., and Millard F.J.C. Pulmonary arterial hypertension and emphysema. Br J Dis Chest 78 (1984) 211-216
92. Larsson L.-G., Lindberg A., Franklin K.A., and Lundbäck B. Symptoms related to obstructive sleep apnoea are common in subjects with asthma, chronic bronchitis and rhinitis in a general population. Respir Med 95 (2001) 423-429
93. Campbell A.H., and Lee E.J. The relationship between lung cancer and chronic bronchitis. Br J Dis Chest 57 (1963) 113-119
94. Garcia-Aymerich J., Sunyer J., Domingo-Salvany A., Mcfarlane D., Montella N., Pérez G., et al. Differences in mortality between patients attending the emergency room services for asthma and chronic obstructive pulmonary disease. Respir Med 93 (1999) 822-826
95. Pauwels R., Calverley P., Buist A.S., Rennard S., Fukuchi Y., Stahl E., et al. COPD exacerbations: the importance of a standard definition. Respir Med 98 (2004) 99-107
96. Miravitlles M, Anzueto A, Legnani D, Forstmeier L, Fargel M. Patient's perception of exacerbations of COPD-the PERCEIVE study. Respir Med 2006; August 26; Epub ahead of print.
97. McHardy V.U., Inglis J.M., Calder M.A., Crofton J.W., Gregg I., Ryland D.A., et al. A study of infective and other factors in exacerbations of chronic bronchitis. Br J Dis Chest 74 (1980) 228-238
98. Calder M.A., Lutz W., and Schonell M.E. A five year study of bacteriology and prophylactic chemotherapy in patients with chronic bronchitis. Br J Dis Chest 62 (1968) 93-99
99. Ellis D.A., Anderson I.M.E., Stewart S.M., Calder J., and Crofton J.W. Exacerbations of chronic bronchitis: exogenous or endogenous infection?. Br J Dis Chest 72 (1978) 115-121
100. Miravitlles M., Llor C., Naberan K., Cots J.M., and Molina J. Variables associated with recovery from acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease. Respir Med 99 (2005) 955-965
101. Lau A.C.-W., Yam L.Y.C.E., and Poon E. Hospital re-admission in patients with acute exacerbation of chronic obstructive pulmonary disease. Respir Med 95 (2001) 876-884
102. Celli B., Goldstein R., Jardim J., and Knobil K. Future perspectives in COPD. Respir Med 99 (2005) S41-S48
103. May J.R. The laboratory background to the use of penicillin in chronic bronchitis and bronchiectasis. Br J Tuberc Dis Chest 49 (1955) 166-173
104. Cazzola M., and Matera M.G. Interrelationship between pharmacokinetics and pharmacodynamics in choosing the appropriate antibiotic and the dosage regimen for treating acute exacerbations of chronic bronchitis. Respir Med 92 (1998) 895-901
105. May J.R. The bacteriology and chemotherapy of chronic bronchitis. Br J Dis Chest 59 (1965) 57-65
106. Allan G.W., Fallon R.J., Lees A.W., Smith J., and Tyrrell W.F. A comparison between ampicillin and tetracycline in purulent chronic bronchitis. Br J Dis Chest 60 (1966) 40-43
107. Pines A., Raafat H., Plucinski K., Greenfield J.S.B., and Linsell W.D. Cephaloridine compared with penicillin and streptomycin in chronic purulent bronchitis: controlled trials of increasing dosage of cephaloridine. Br J Dis Chest 61 (1967) 101-110
108. Calder M.A., Lutz W., and Schonell M.E. A five year study of bacteriology and prophylactic chemotherapy in patients with chronic bronchitis. Br J Dis Chest 62 (1968) 93-99
109. Pines A., Raafat H., Plucinski K., Greenfield J.S.B., Linsell W.D., and Solari M.E. Demethylchlortetracycline, lymecycline and methacycline compared in patients with purulent exacerbations of bronchitis. Br J Dis Chest 62 (1968) 19-26
110. Pines A., Raafat H., Plucinski K., Greenfield J.S.B., and Solari M. A comparison of erythromycin, novobiocin, tetracycline and a novobiocin-tetracycline combination in purulent exacerbations of chronic bronchitis. Br J Dis Chest 63 (1969) 206-214
111. Vandenbergh E., Clément J., and van de Woestijne K.P. Prevention of exacerbations of bronchitis: trial of a long acting sulphonamide. Br J Dis Chest 64 (1970) 58-62
112. Pines A., Raafat H., Greenfield J.S., Marshall M.J., and Solari M. Penicillin, ampicillin and cephaloridine in severe exacerbations of purulent chronic bronchitis in elderly patients. Br J Dis Chest 65 (1971) 91-97
113. Ingold A., and Shaylor J.M. The influence of bromhexine (Biosolvon) on the levels of ampicillin and oxytetracycline in sputum. Br J Dis Chest 65 (1971) 243-246
114. Pines A., Raafat H., Greenfield J.S., Linsell W.D., and Solari M.E. Antibiotic regimens in moderately ill patients with purulent exacerbations of chronic bronchitis. Br J Dis Chest 66 (1972) 107-115
115. Pines A., Greenfield J.S., Raafat H., and Siddiqui G. Chloramphenicol and ampicillin compared in elderly patients with severe purulent exacerbations of bronchitis. Br J Dis Chest 66 (1972) 116-120
116. Research Committee of the British Thoracic and Tuberculosis Association-The Clinical Trials Subcommittee. A comparison of trimethoprim-sulphamethoxazole compound and tetracycline in exacerbations of chronic bronchitis. A double-blind multi-centre trial on in-patients. Br J Dis Chest 66 (1972) 199-206
117. Darke C.S., Weber J.C., and Beeley J.M. Sulfametopyrazine in the prophylaxis of exacerbations of chronic bronchitis. Br J Dis Chest 66 (1972) 276-283
118. Ross G.I., and Croydon E.A. A winter-long trial of ampicillin in chronic bronchitis. Br J Dis Chest 67 (1973) 153-160
119. Pines A., Greenfield J.S., Raafat H., and Sreedharan K.S. A comparison of pivampicillin and ampicillin in exacerbations of chronic bronchitis. Br J Dis Chest 67 (1973) 221-226
120. Huddy R.B., Jones D.M., and Lee H.Y. Tetracycline and co-trimoxazole in acute exacerbations of chronic bronchitis. Br J Dis Chest 67 (1973) 241-245
121. Research Committee of the British Thoracic and Tuberculosis Association-The Clinical Trials Subcommittee. Doxycycline and oxytetracycline in bronchitis: a double blind controlled trial. Br J Dis Chest 67 (1973) 114-118
122. Davies D., and Darke C.S. Sulfametopyrazine prophylaxis in chronic bronchitis. Br J Dis Chest 72 (1978) 231-234
123. Willey R.F., Gould J.C., and Grant I.W. A comparison of ampicillin, erythromycin and erythromycin with sulphametopyrazine in the treatment of infective exacerbations of chronic bronchitis. Br J Dis Chest 72 (1978) 13-20
124. Pines A., and Raafat H. Cefuroxime in severe respiratory infections: a double-blind comparison of two doses. Br J Dis Chest 73 (1979) 395-398
125. Mackay A.D. Amoxycillin versus ampicillin in treatment of exacerbations of chronic bronchitis. Br J Dis Chest 74 (1980) 379-384
126. Wood J.B., and Alexander A.M. A retrospective comparison of ampicillin and amoxycillin in chest infections. Br J Dis Chest 76 (1982) 234-236
127. Anderson G., Peel E.T., Payne H., and Ruth P. A single dose of sulfametopyrazine versus 7 days of ampicillin in acute on chronic bronchitis. Br J Dis Chest 79 (1985) 258-261
128. Trigg C.J., Wilks M., Herdman M.J., Clague J.E., Tabaqchali S., and Davies R.J. A double-blind comparison of the effects of cefaclor and amoxycillin on respiratory tract and oropharyngeal flora and clinical response in acute exacerbations of bronchitis. Respir Med 85 (1991) 301-308
129. Read R.C., Kuss A., Berrisoul F., Kearsley N., Torres A., and Kubin R. The efficacy and safety of a new ciprofloxacin suspension compared with co-amoxiclav tablets in the treatment of acute exacerbations of chronic bronchitis. Respir Med 93 (1999) 252-261
130. Chodosh S., DeAbate C.A., Haverstock D., Aneiro L., and Church D. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Respir Med 94 (2000) 18-27
131. DeAbate C.A., Mathew C.P., Warner J.H., Heyd A., and Church D. The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis. Respir Med 94 (2000) 1029-1037
132. Aubier M., Aldons P.M., Leak A., McKeith D.D., Leroy B., Rangaraju M., et al. Telithromycin is as effective as amoxicillin/clavulanate in acute exacerbations of chronic bronchitis. Respir Med 96 (2002) 862-871
133. Wilson R., Langan C., Ball P., Bateman K., and Pypstra R. Oral gemifloxacin once daily for 5 days compared with sequential therapy with i.v. ceftriaxone/oral cefuroxime (maximum of 10 days) in the treatment of hospitalized patients with acute exacerbations of chronic bronchitis. Respir Med 97 (2003) 242-249
134. Sethi S., Fogarty C., and Fulambarker A. A randomized, double-blind study comparing 5 days oral gemifloxacin with 7 days oral levofloxacin in patients with acute exacerbation of chronic bronchitis. Respir Med 98 (2004) 697-707
135. Urueta-Robledo J., Ariza H., Jardim J.R., Caballero A., Garcia-Calderon A., Amabile-Cuevas C.F., et al. Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: the Latin American Cohort. Respir Med 100 (2006) 1504-1511
136. Banerjee D., Khair O.A., and Honeybourne D. The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD. Respir Med 99 (2005) 208-215
137. Miravitlles M., Mayordomo C., Artes M., Sanchez-Agudo L., Nicolau F., and Segu J.L. Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice. EOLO Group. Estudio Observacional de la Limitacion Obstructiva al Flujo aEreo. Respir Med 93 (1999) 173-179
138. Hasani A., Pavia D., Rotondetto S., Clarke S.W., Spiteri M.A., and Agnew J.E. Effect of oral antibiotics on lung mucociliary clearance during exacerbation of chronic obstructive pulmonary disease. Respir Med 92 (1998) 442-447
139. Cazzola M., Salzillo A., De Giglio C., Piccolo A., Califano C., and Noschese P. Treatment of acute exacerbation of severe-to-very severe COPD with azithromycin in patients vaccinated against Streptococcus pneumoniae. Respir Med 99 (2005) 663-669
140. Feinman L., and Newell D.J. Isoprenaline in the treatment of chronic bronchitis: a controlled trial of different methods of administration. Br J Dis Chest 57 (1963) 140-146
141. Berend N., Webster J., and Marlin G.E. Salbutamol by pressure-packed aerosol and by intermittent positive pressure ventilation in chronic obstructive bronchitis. Br J Dis Chest 72 (1978) 122-124
142. Lightbody I.M., Ingram C.G., Legge J.S., and Johnston R.N. Ipratropium bromide, salbutamol and prednisolone in bronchial asthma and chronic bronchitis. Br J Dis Chest 72 (1978) 181-186
143. Connolly C.K. The effect of bronchodilators on diurnal rhythms in airway obstruction. Br J Dis Chest 75 (1981) 197-203
144. Jenkins P.F., White J.P., Jariwalla A.J., Anderson G., and Campbell I.A. A controlled study of slow-release theophylline and aminophylline in patients with chronic bronchitis. Br J Dis Chest 76 (1982) 57-60
145. Anderson G., Peel E.T., Pardoe T., and Jones R. Sustained-release theophylline in chronic bronchitis. Br J Dis Chest 76 (1982) 261-265
146. Winter R.J., Langford J.A., George R.J., Deacock S.J., and Rudd R.M. The effects of theophylline and salbutamol on right and left ventricular function in chronic bronchitis and emphysema. Br J Dis Chest 78 (1984) 358-362
147. Jenkins S.C., and Moxham J. High dose salbutamol in chronic bronchitis: comparison of 400 μg, 1 mg, 1.6 mg, 2 mg and placebo delivered by Rotahaler. Br J Dis Chest 81 (1987) 242-247
148. Allen M.B., Pugh J., and Wilson R.S. Nebuhaler or nebulizer for high dose bronchodilator therapy in chronic bronchitis: a comparison. Br J Dis Chest 82 (1988) 368-373
149. Rosenkranz B., Rouzier R., Kruse M., Dobson C., Ayre G., Horowitz A., et al. Safety and tolerability of high-dose formoterol (via Aerolizer) and salbutamol in patients with chronic obstructive pulmonary disease. Respir Med 100 (2006) 666-672
150. Hansen N.C., Evald T., and Ibsen T.B. Terbutaline inhalations by the Turbuhaler as replacement for domiciliary nebulizer therapy in severe chronic obstructive pulmonary disease. Respir Med 88 (1994) 267-271
151. Hansen N.C., and Andersen P.B. Salbutamol powder inhaled from the Diskhaler compared to salbutamol as nebulizer solution in severe chronic airways obstruction. Respir Med 89 (1995) 175-179
152. Cazzola M., Matera M.G., Santangelo G., Vinciguerra A., Rossi F., and D'Amato G. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir Med 89 (1995) 357-362
153. Cazzola M., Matera M.G., Di Perna F., Calderaro F., Califano C., and Vinciguerra A. A comparison of bronchodilating effects of salmeterol and oxitropium bromide in stable chronic obstructive pulmonary disease. Respir Med 92 (1998) 354-357
154. Cazzola M., Vinciguerra A., Di Perna F., and Matera M.G. Early reversibility to salbutamol does not always predict bronchodilation after salmeterol in stable chronic obstructive pulmonary disease. Respir Med 92 (1998) 1012-1016
155. Patakas D., Andreadis D., Mavrofridis E., and Argyropoulou P. Comparison of the effects of salmeterol and ipratropium bromide on exercise performance and breathlessness in patients with stable chronic obstructive pulmonary disease. Respir Med 92 (1998) 1116-1121
156. 2-agonists in COPD. Respir Med 94 Suppl E (2000) S1-S5
157. Lötvall J. Pharmacology of bronchodilators used in the treatment of COPD. Respir Med 94 Suppl E (2000) S6-S10
158. Matera M.G., Caputi M., and Cazzola M. A combination with clinical recommended dosages of salmeterol and ipratropium is not more effective than salmeterol alone in patients with chronic obstructive pulmonary disease. Respir Med 90 (1996) 497-499
159. Cazzola M., Matera M.G., Di Perna E., Califano C., D'Amato M., and Mazzarella G. Influence of higher than conventional doses of oxitropium bromide on formoterol-induced bronchodilation in COPD. Respir Med 93 (1999) 909-911
160. 2-agonists be considered an alternative first choice option for the treatment of stable COPD?. Respir Med 93 (1999) 227-229
161. Benhamou D., Cuvelier A., Muir J.F., Leclerc V., Le Gros V., Kottakis J., et al. Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk). Respir Med 95 (2001) 817-821
162. Cazzola M., Di Perna F., D'Amato M., Califano C., Matera M.G., and D'Amato G. Formoterol Turbuhaler for as-needed therapy in patients with mild acute exacerbations of COPD. Respir Med 95 (2001) 917-921
163. Liesker J.J., Van De Velde V., Meysman M., Vincken W., Wollmer P., Hansson L., et al. Effects of formoterol (Oxis Turbuhaler) and ipratropium on exercise capacity in patients with COPD. Respir Med 96 (2002) 559-566
164. Cazzola M., Califano C., Di Perna F., D'Amato M., Terzano C., Matera M.G., et al. Acute effects of higher than customary doses of salmeterol and salbutamol in patients with acute exacerbation of COPD. Respir Med 96 (2002) 790-795
165. Jones P.W., Wilson K., and Sondhi S. Cost-effectiveness of salmeterol in patients with chronic obstructive pulmonary disease: an economic evaluation. Respir Med 97 (2003) 20-26
166. Ringbaek T., and Viskum K. Is there any association between inhaled ipratropium and mortality in patients with COPD and asthma?. Respir Med 97 (2003) 264-272
167. Cazzola M., Santus P., Matera M.G., Carlucci P., Belloli E., Di Marco F., et al. A single high dose of formoterol is as effective as the same dose administered in a cumulative manner in patients with acute exacerbation of COPD. Respir Med 97 (2003) 458-462
168. 2-agonist in COPD: relationship to atopy and neutrophil activation. Respir Med 97 (2003) 591-598
169. Donohue J.F., Menjoge S., and Kesten S. Tolerance to bronchodilating effects of salmeterol in COPD. Respir Med 97 (2003) 1014-1020
170. Cazzola M., Centanni S., Santus P., Verga M., Mondoni M., di Marco F., et al. The functional impact of adding salmeterol and tiotropium in patients with stable COPD. Respir Med 98 (2004) 1214-1221
171. Chopra N., Williams M., Rimmer M., Kahl L., and Jenkins M. Salmeterol HFA is as effective as salmeterol CFC in children and adults with persistent asthma. Respir Med 99 Suppl A (2005) S1-S10
172. Cazzola M., Noschese P., Salzillo A., De Giglio C., D'Amato G., and Matera M.G. Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients. Respir Med 99 (2005) 524-528
173. Molimard M., Bourcereau J., Le Gros V., and Bourdeix I. Total reversibility testing as indicator of the clinical efficacy of formoterol in COPD. Respir Med 99 (2005) 695-702
174. Campbell M., Eliraz A., Johansson G., Tornling G., Nihlen U., Bengtsson T., et al. Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease. Respir Med 99 (2005) 1511-1520
175. Adams S.G., Anzueto A., Briggs Jr. D.D., Menjoge S.S., and Kesten S. Tiotropium in COPD patients not previously receiving maintenance respiratory medications. Respir Med 100 (2006) 1495-1503
176. 2-agonist induced bronchodilation in mechanically ventilated COPD patients: a prospective clinical study. Respir Med 2006 June 13; Epub ahead of print.
177. Iacono P., Velicitat P., Guemas E., Leclerc V., and Thebault J.J. Improved delivery of ipratropium bromide using Respimat (a new soft mist inhaler) compared with a conventional metered dose inhaler: cumulative dose response study in patients with COPD. Respir Med 94 (2000) 490-495
178. Centanni S., Santus P., Casanova F., Carlucci P., Boveri B., Castagna F., et al. Bronchodilating effect of oxitropium bromide in heart disease patients with exacerbations of COPD: double-blind, randomized, controlled study. Respir Med 96 (2002) 137-1341
179. Bellia V., Foresi A., Bianco S., Grassi V., Olivieri D., Bensi G., et al. Efficacy and safety of oxitropium bromide, theophylline and their combination in COPD patients: a double-blind, randomized, multicentre study (BREATH Trial). Respir Med 96 (2002) 881-889
180. Ringbaek T., and Viskum K. Is there any association between inhaled ipratropium and mortality in patients with COPD and asthma?. Respir Med 97 (2003) 264-272
181. Kilfeather S.A., Ponitz H.H., Beck E., Schmidt P., Lee A., Bowen I., et al. Improved delivery of ipratropium bromide/fenoterol from Respimat Soft Mist Inhaler in patients with COPD. Respir Med 98 (2004) 387-397
182. Poole P.J., Saini R., Brodie S.M., and Black P.N. Comparison of the effects of nebulised and inhaled salbutamol on breathlessness in severe COPD. Respir Med 99 (2005) 372-376
183. Ohta K., Fukuchi Y., Grouse L., Mizutani R., Rabe K.F., Rennard S.I., et al. A prospective clinical study of theophylline safety in 3810 elderly with asthma or COPD. Respir Med 98 (2004) 1016-1024
184. Ram F.S., Jardin J.R., Atallah A., Castro A.A., Mazzini R., Goldstein R., et al. Efficacy of theophylline in people with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. Respir Med 99 (2005) 135-144
185. Di Marco F, Verga M, Santus P, Morelli N, Cazzola M, Centanni S. Effect of formoterol, tiotropium, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease: a pilot study. Respir Med 2006 April 18; Epub ahead of print.
186. Ogilvie A.G. The treatment of patients with severe asthma and chronic bronchitis. Br J Tuberc Dis Chest 52 (1958) 126-133
187. Ogilvie A.G., and Newell D.J. A maintenance trial of combined steroid and antibiotic treatment in a series of asthmatics with chronic bronchitis. Br J Dis Chest 54 (1960) 308-320
188. Man S.F., and Sin D.D. Inhaled corticosteroids in chronic obstructive pulmonary disease: is there a clinical benefit?. Drugs 65 (2005) 579-591
189. Hurford J.V., Little G.M., and Loudon H.W.G. The use of prednisolone in chronic bronchitis. Br J Dis Chest 57 (1963) 133-139
190. Wilcke J.T., and Dirksen A. The effect of inhaled glucocorticosteroids in emphysema due to alpha1-antitrypsin deficiency. Respir Med 91 (1997) 275-279
191. Ström K. Oral corticosteroid treatment during long-term oxygen therapy in chronic obstructive pulmonary disease: a risk factor for hospitalization and mortality in women. Respir Med 92 (1998) 50-56
192. Corden Z., and Rees P.J. The effect of oral corticosteroids on bronchodilator responses in COPD. Respir Med 92 (1998) 279-282
193. Jarad N.A., Wedzicha J.A., Burge P.S., and Calverley P.M. An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. Respir Med 93 (1999) 161-166
194. Senderovitz T., Vestbo J., Frandsen J., Maltbaek N., Norgaard M., Nielsen C., et al. Steroid reversibility test followed by inhaled budesonide or placebo in outpatients with stable chronic obstructive pulmonary disease. Respir Med 93 (1999) 715-718
195. Loppow D., Schleiss M.B., Kanniess F., Taube C., Jorres R.A., and Magnussen H. In patients with chronic bronchitis a four week trial with inhaled steroids does not attenuate airway inflammation. Respir Med 95 (2001) 115-121
196. Sandek K., Bratel T., and Lagerstrand L. Effects on diffusing capacity and ventilation-perfusion relationships of budesonide inhalations for 2 months in chronic obstructive pulmonary disease (COPD). Respir Med 95 (2001) 676-684
197. Ayres J.G., Price M.J., and Efthimiou J. Cost-effectiveness of fluticasone propionate in the treatment of chronic obstructive pulmonary disease: a double-blind randomized, placebo-controlled trial. Respir Med 97 3 (2003) 212-220
198. van Grunsven P., Schermer T., Akkermans R., Albers M., van den Boom G., van Schayck O., et al. Short- and long-term efficacy of fluticasone propionate in subjects with early signs and symptoms of chronic obstructive pulmonary disease. Results of the DIMCA study. Respir Med 97 (2003) 1303-1312
199. Sadowska A.M., van Overveld F.J., Gorecka D., Zdral A., Filewska M., Demkow U.A., et al. The interrelationship between markers of inflammation and oxidative stress in chronic obstructive pulmonary disease: modulation by inhaled steroids and antioxidant. Respir Med 99 (2005) 241-249
200. Zietkowski Z., Kucharewicz I., and Bodzenta-Lukaszyk A. The influence of inhaled corticosteroids on exhaled nitric oxide in stable chronic obstructive pulmonary disease. Respir Med 99 (2005) 816-824
201. John M., Bosse S., Oltmanns U., Schumacher A., and Witt C. Effects of inhaled HFA beclomethasone on pulmonary function and symptoms in patients with chronic obstructive pulmonary disease. Respir Med 99 (2005) 1418-1424
202. Ozol D., Aysan T., Solak Z.A., Mogulkoc N., Veral A., and Sebik F. The effect of inhaled corticosteroids on bronchoalveolar lavage cells and IL-8 levels in stable COPD patients. Respir Med 99 (2005) 1494-1500
203. Tkacova R., Toth S., and Sin D.D. Inhaled corticosteroids and survival in COPD patients receiving long-term home oxygen therapy. Respir Med 100 (2006) 385-392
204. Cazzola M., Santus P., Di Marco F., Boveri B., Castagna F., Carlucci P., et al. Bronchodilator effect of an inhaled combination therapy with salmeterol+fluticasone and formoterol+budesonide in patients with COPD. Respir Med 97 (2003) 453-457
205. Vestbo J., Soriano J.B., Anderson J.A., Calverley P., Pauwels R., and Jones P. Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respir Med 98 (2004) 1045-1050
206. Kiri V.A., Bettoncelli G., Testi R., and Viegi G. Inhaled corticosteroids are more effective in COPD patients when used with LABA than with SABA. Respir Med 99 (2005) 1115-1124
207. 2-agonists in a health maintenance organization. Respir Med 99 (2005) 1534-1545
208. Cazzola M., Noschese P., De Michele F., D'Amato G., and Matera M.G. Effect of formoterol/budesonide combination on arterial blood gases in patients with acute exacerbation of COPD. Respir Med 100 (2006) 212-217
209. Mapel D.W., Hurley J.S., Roblin D., Roberts M., Davis K.J., Schreiner R., et al. Survival of COPD patients using inhaled corticosteroids and long-acting β agonists. Respir Med 100 (2006) 595-609
210. Anderson G. A clinical trial of a mucolytic agent-acetylcysteine-in chronic bronchitis. Br J Dis Chest 60 (1966) 101-103
211. Palmer K.N. Sputum liquefiers. Br J Dis Chest 60 (1966) 177-181
212. Marriott C., and Richards J.H. The effects of storage and of potassium iodide, urea, N-acetyl-cysteine and triton X-100 on the viscosity of bronchial mucus. Br J Dis Chest 68 (1974) 171-182
213. Millar A.B., Pavia D., Agnew J.E., Lopez-Vidriero M.T., Lauque D., and Clarke S.W. Effect of oral N-acetylcysteine on mucus clearance. Br J Dis Chest 79 (1985) 262-266
214. Parr G.D., and Huitson A. Oral Fabrol (oral N-acetyl-cysteine) in chronic bronchitis. Br J Dis Chest 81 (1987) 341-348
215. Dueholm M., Nielsen C., Thorshauge H., Evald T., Hansen N.C., Madsen H.D., et al. N-acetylcysteine by metered dose inhaler in the treatment of chronic bronchitis: a multi-centre study. Respir Med 86 (1992) 89-92
216. Hansen N.C., Skriver A., Brorsen-Riis L., Balslov S., Evald T., Maltbaek N., et al. Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis. Respir Med 88 (1994) 531-535
217. Decramer M., Rutten-van Molken M., Dekhuijzen P.N., Troosters T., van Herwaarden C., Pellegrino R., et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 365 (2005) 1552-1560
218. Gillissen A., Jaworska M., Orth M., Coffiner M., Maes P., App E.M., et al. Nacystelyn, a novel lysine salt of N-acetylcysteine, to augment cellular antioxidant defence in vitro. Respir Med 91 (1997) 159-168
219. Gillissen A., and Nowak D. Characterization of N-acetylcysteine and ambroxol in anti-oxidant therapy. Respir Med 92 (1998) 609-623
220. Matsumoto K., Hashimoto S., Gon Y., Nakayama T., Takizawa H., and Horie T. N-acetylcysteine inhibits IL-1 α-induced IL-8 secretion by bronchial epithelial cells. Respir Med 92 (1998) 512-515
221. Kasielski M., and Nowak D. Long-term administration of N-acetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease. Respir Med 95 (2001) 448-456
222. Jiang M.Z., Tsukahara H., Hayakawa K., Todoroki Y., Tamura S., Ohshima Y., et al. Effects of antioxidants and NO on TNF-α-induced adhesion molecule expression in human pulmonary microvascular endothelial cells. Respir Med 99 (2005) 580-591
223. van Schayck C.P., Dekhuijzen P.N., Gorgels W.J., van Grunsven P.M., Molema J., van Herwaarden C.L., et al. Are anti-oxidant and anti-inflammatory treatments effective in different subgroups of COPD? A hypothesis. Respir Med 92 (1998) 1259-1264
224. Rubinstein I., Kumar B., and Schriever C. Long-term montelukast therapy in moderate to severe COPD-a preliminary observation. Respir Med 98 (2004) 134-138
225. Vignola A.M. PDE4 inhibitors in COPD-a more selective approach to treatment. Respir Med 98 (2004) 495-503
226. Svartberg J., Aasebo U., Hjalmarsen A., Sundsfjord J., and Jorde R. Testosterone treatment improves body composition and sexual function in men with COPD, in a 6-month randomized controlled trial. Respir Med 98 (2004) 906-913
227. Gronke L., Schlenker J., Holz O., Out T.A., Magnussen H., and Jorres R.A. Effect of cetirizine dihydrochloride on the airway response to hypertonic saline aerosol in patients with chronic obstructive pulmonary disease (COPD). Respir Med 99 (2005) 1241-1248
228. Lee S.Y., Kang E.J., Hur G.Y., Jung K.H., Jung H.C., Lee S.Y., et al. The inhibitory effects of rebamipide on cigarette smoke-induced airway mucin production. Respir Med 100 (2006) 503-511
229. Sans-Torres J., Domingo C., Moron A., Rue M., and Marin A. Long-term effects of almitrine bismesylate in COPD patients with chronic hypoxaemia. Respir Med 97 (2003) 599-605
230. Pinet C., Tessonnier F., Ravel T., and Orehek J. Association of oral almitrine and medroxyprogesterone acetate: effect on arterial blood gases in chronic obstructive pulmonary disease. Respir Med 95 (2001) 602-605
231. Nakos G., Evrenoglou D., Vassilakis N., and Lampropoulos S. Haemodynamics and gas exchange in liver cirrhosis: the effect of orally administered almitrine bismesylate. Respir Med 87 (1993) 93-98
232. Hanania N.A., Ambrosino N., Calverley P., Cazzola M., Donner C.F., and Make B. Treatments for COPD. Respir Med 99 (2005) S28-S40
233. Jones P., Lareau S., and Mahler D.A. Measuring the effects of COPD on the patient. Respir Med 99 (2005) S11-S18
234. Eaton T., Lewis C., Young P., Kennedy Y., Garrett J.E., and Kolbe J. Long-term oxygen therapy improves health-related quality of life. Respir Med 98 (2004) 285-293
235. 2 above 60 mm Hg. Am Rev Respir Dis 145 (1992) 1070-1076
236. Plywaczewski R., Sliwinski P., Nowinski A., Kaminski D., and Zielinski J. Incidence of nocturnal desaturation while breathing oxygen in COPD patients undergoing long-term oxygen therapy. Chest 117 (2000) 679-683
237. Bloom B.S., Daniel J.M., Wiseman M., Knorr R.S., Cebul R., and Kissick W.L. Transtracheal oxygen delivery and patients with chronic obstructive disease. Respir Med 83 (1989) 281-288
238. Shapiro S.H., Ernst P., Gray-Donald K., Martin J.G., Wood-Dauphinee S., Beaupre A., et al. Effect of negative pressure ventilation in severe chronic obstructive pulmonary disease. Lancet 340 (1992) 1425-1429
239. Strumpf D.A., Millman R.P., Carlisle C.C., Grattan L.M., Ryan S.M., Erickson A.D., et al. Nocturnal positive-pressure ventilation via nasal mask in patients with severe chronic obstructive pulmonary disease. Am Rev Respir Dis 144 (1991) 1234-1239
240. Meecham Jones D.J., Paul E.A., Grahame-Clarke C., and Wedzicha J.A. Nasal pressure support ventilation plus oxygen compared with oxygen therapy alone in hypercapnic COPD. Am J Respir Crit Care Med 152 (1995) 538-544
241. Muir J.F., Cuvelier A., and Tenang B. Long-term home nasal intermittent positive pressure ventilation (NIPPV) plus oxygen therapy (LTOT) versus LTOT alone in severe hypercapnic COPD. Preliminary results of a European multicentre trial. Am J Respir Crit Care Med 155 (1997) A408
242. Clini E., Sturani C., Rossi A., Viaggi S., Corrado A., Donner C.F., et al. The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. Eur Respir J 20 (2002) 529-538
243. Gray Jr. F.D., and MacIver S. The use of inspiratory positive pressure breathing in cardio-pulmonary diseases. Br J Tuberc Dis Chest 52 (1958) 2-10
244. The National Emphysema Treatment Trial Research Group. Rationale and design of The National Emphysema Treatment Trial: a prospective randomized trial of lung volume reduction surgery. Chest 116 (1999) 1750-1761
245. Fishman A., Martinez F., Naunheim K., Piantadosi S., Wise R., et al., National Emphysema Treatment Trial Research Group. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 248 (2003) 2059-2073
246. Reardon J., Casaburi R., Morgan M., Nici L., and Rochester C. Pulmonary rehabilitation for COPD. Respir Med 99 (2005) S19-S27
247. Folgering H., and van Herwaarden C. Pulmonary rehabilitation in asthma and COPD, physiological basics. Respir Med 87 Suppl B (1993) 41-44
248. Williams P., Smith C.M., and McGavin C.R. Diaphragmatic breathing training and walking performance in chronic airways obstruction. Br J Dis Chest 76 (1982) 164-166
249. Singh S.J., Smith D.L., Hyland M.E., and Morgan M.D. A short outpatient pulmonary rehabilitation programme: immediate and longer term effects on exercise performance and quality of life. Respir Med 92 (1998) 1146-1154